State Senator Carla Nelson explains how the pharmaceutical industry is reacting to her bill requiring payers to cover all approved biosimilars and reference products.
Why is Minnesota a good place to try a bill of this type, especially since it's the first of its kind in the country?
Nelson: Well, I think Minnesota is a great place, because number 1: we like to be a state of innovation. Whether it be education or in other areas, Minnesota is an innovator. Secondly, we are a hotbed of excellent health care. And I'll give a shout-out to the Mayo Clinic, which is in my district in Rochester. We have a number of gold standard health care providers in our state. We also are a state known for medical innovation, and so a medical ally comes to mind. So, Minnesota is the place to do this. And I'm very proud of the fact that our first biosimilar bill actually passed before we even had 1 biosimilar in our nation. And the point is, we should be on the cutting edge of this and Minnesota can lead. It will be great for our citizens and it will also be great for those [companies] who will continue to [develop] those biosimilars that will have the same outcomes, but at a much lower cost.
What are the politics involved here and are you feeling any pushback from the payer or manufacturer community?
Nelson: There's always pushback to change, and the key is really listening to those objections—really trying to sort out which ones are objections that matter, [such as] how is it affecting the patient? How is it affecting the doctor-patient relationship? How is it affecting the cost and the choice? So, those are the things that really come to the front. I'm very pleased with the language we have in [the bill, addressing] wholesale cost and covering biosimilars that are at a lower cost. I think those are 2 really key pieces that are going to help drive this to fruition and actually incentivize more biosimilars and get lower-cost of drugs to our patients on time without needing to go through the delay of prior authorization. And I think our medical providers will appreciate as well that these things are covered on the formulary, so they don't have to go through the cycle of paperwork for things like prior authorizations.
To read more about SF 990, click here.
To hear about this bill from State Representative Jennifer Schultz, co-author of SF 990, click here.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.